Article
Healthy, mtDNA-mutation free mesoangioblasts from mtDNA patients qualify for autologous therapy.
Stem cell research & therapy - 21 Dec 2019
van Tienen Florence, Zelissen Ruby, Timmer Erika, van Gisbergen Marike, Lindsey Patrick, Quattrocelli Mattia, Sampaolesi Maurilio, Mulder-den Hartog Elvira, de Coo Irenaeus, Smeets Hubert
Abstract excerpt
BACKGROUND: Myopathy and exercise intolerance are prominent clinical features in carriers of a point-mutation or large-scale deletion in the mitochondrial DNA (mtDNA). In the majority of patients, the mtDNA mutation is heteroplasmic with varying mutation loads between tissues of an individual. Exercise-induced muscle regeneration has been shown to be beneficial in some mtDNA mutation carriers, but is often not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.